Disclosures: Pinzhu Huang: Nothing to Disclose, Guangyan Wei: Nothing to Disclose, Jesse Kirkpatrick: Nothing to Disclose, MARAM ALENZI: Nothing to Disclose, Yi Lin: Nothing to Disclose, Li Tan: Nothing to Disclose, Disha Badlani: Nothing to Disclose, Li Chen: Nothing to Disclose, Mathieu Petitijean: Nothing to Disclose, Kahini Vaid: Nothing to Disclose, Shuangshuang Zhao: Nothing to Disclose, Alicia lugovskoy: Nothing to Disclose, Xin Chen: Nothing to Disclose, Gregory Gores: Nothing to Disclose, Yury Popov: Nothing to Disclose 1939 EVALUATING TREATMENT STRATEGIES IN HEPATOCELLULAR CARCINOMA: A LONGITUDINAL ANALYSIS OF BCLC RECOMMENDATIONS AND PATIENT OUTCOMES Eleonora Alimenti 1 Massimo Iavarone 1 Lorenzo Canova 1 Mariangela Bruccoleri 1 Barbara Antonelli 1 Anna Maria Ierardi 1 Angelo Sangiovanni 1 Annalisa De Silvestri 2 Pietro Lampertico 3 , 1 Foundation IRCCS Ca Granda Ospedale Maggiore Policlinico, Milan, Italy, 2 Clinical Epidemiology and Biometry Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, 3 Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico Background: In 2022 the BCLC staging and treatment algorithm for hepatocellular carcinoma (HCC) management has been updated (BCLC_2022), granting for higher flexibility and customized management for HCC patients as compared to the 2018 version
10.1016/j.neulet.2006.11.058 Neurosci
Mechanistic analysis using endocytosis pathway inhibitors indicated that PTX-CDs predominantly traverse the BBB via macropinocytosis, highlighting the involvement of energy-dependent vesicular uptake mechanisms in BBB translocation [148]
doi: 10.1038/s41575-020-0331-7 80 FranzosaEASirota-MadiAAvila-PachecoJFornelosNHaiserHJReinkerSet al
